Introduction to the art & science of psilocybin therapy

Brian D. Richards, PsyD
William A. Richards, PhD

Psychedelic therapy for end-of-life and palliative care

Manish Agrawal, MD, Betsy Jenkins, Norma Mancini Stevens, MS, LCPC, NCC, and Mark Bates

Introduction to psychedelic therapy for addiction

Matthew W. Johnson, PhD

Introduction to Psychedelic Law Practice and Policy for Attorneys

Hadas Alterman, JD, Karina A. Bashir, Esq., Matthew Brockmeier, Allison Hoots, Adriana Kertzner, JD, Victoria Litman, MDiv, JD, LLM, Graham Pechenik, JD, and Perry N. Salzhauer, JD

Guiding psilocybin therapy sessions with a focus on integration

Mary Cosimano, LMSW

Doors open

Opening remarks



Opening address

The state of the psychedelic industry

An overview of the state of the industry, and reflections on the last year.

Dan Grossman, PhD

Managing Director & Senior Partner, BCG

Standing at the threshold: A view from MAPS PBC Chairman Jeff George

After nearly twenty years of studies on the potential of MDMA-assisted therapy for the treatment of PTSD, MAPS Public Benefit Corporation is preparing to submit a New Drug Application to the FDA in late 2023, with a response anticipated in 2024.

In this session, MAPS PBC Chairman of the Board Jeff George, former global CEO of Sandoz and Alcon at Novartis Group, shares an update on MAPS PBC's plans for commercialization, and his thoughts on the need for industry-wide cooperation to ensure the safety and success of new treatments requiring drug + therapy in combination.

DISCLAIMER: The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by the FDA or other regulatory authorities, does not work for everyone, and carries risks even in therapeutic settings.

Jeff George

Chairman, MAPS PBC and Managing Partner, Maytal Capital

Mid-morning break

Finding funding for the future

Where will capital for the next generation of clinical research, commercialization, and infrastructure come from? The venture model that fueled the 2020 - 2021 boom seems unlikely to roar back to life.Thus far, the titans of biotech and healthcare funding have remained on the sidelines. Government funding, while up from zero, stands at a trickle, and psychedelics remain niche in the world of philanthropy. In this session, panelists from across the spectrum of finance will address the complexities of funding the next chapter of psychedelic initiatives.

Ritu Baral

Managing Director, Senior Biotechnology Analyst at Cowen and Company



The role of philanthropy in the psychedelic ecosystem

Psychedelics presently occupy a unique position. While public opinion has warmed considerably, and both the academy and regulators are now willing to consider its merits based on the science, psychedelic drugs and therapies still lack a mature industry and capital market, and government funding remains artificially constrained by legacy prohibitionist policies and attitudes.

As public engagement with psychedelics continues to grow and integration with the field of medicine draws nearer, philanthropy has emerged as an essential source of funding for research, policy activism, education, infrastructure, and access projects. Come to this session to learn what is missing from the priorities of profit-focused businesses and state grant makers.

Dara Menashi, PhD

Co-Lead Investigator, Psychedelic Health Equity Initiative

Hanifa Nayo Washington

Healing Justice Advocate, Co-Lead Investigator, Psychedelic Health Equity Initiative, Founding Team Emerita, Fireside Project

Bennett Nemser, MD

Chief Program Officer, Steven & Alexandra Cohen Foundation

Lunch

Insurance, reimbursement, and psychedelic-assisted therapy

Achieving reimbursement from major payors is essential to both ensuring widespread access to psychedelic-assisted therapy for those in need, and also the financial viability of the nascent psychedelic clinical ecosystem.

While in some ways, PAT (Psychedelic Assisted Therapy) resembles other new treatments that initially reach the market without reimbursement. However, in others, PAT remains a sui generis model with unique considerations.

In this session, we will hear about the varieties of payors in the US, and the strategies being pursued to achieve reimbursement for PAT over the short- and long-term.

Neil Leibowitz, MD

Physician Executive, Advisor

Lia Mix, CEO, LMFT

CEO and Founder of Delphi

The greatest teacher: Lessons from failure

During 2020 - 2021, dozens of new psychedelic startups emerged from a frenzy of venture investment and media attention.

Inevitably, many of them reached insurmountable challenges while operating in a brand-new industry, a niche investment bubble, and changing macroeconomic tides-- in addition to the challenges faced by all startups.

In this session, entrepreneurs share their tales and lessons learned from their journeys and conclusions.

Ronan Levy

CEO, Cofounder, and Author, The Non-Ordinary Company Ltd

Mid-afternoon break

Rethinking how we deliver care: An interview with Elliot Cohen

While the market has tightened considerably in recent years, many entrepreneurs are still finding success in starting and growing endeavors in the psychedelic industry.

In this session, we will highlight recent achievements and hear the stories of finding secure footing (and funding) over the last year.

Elliot Cohen

Co-founder, PillPack/Amazon Pharmacy

The last mile: Insights from early service providers

While nearly all funding in the field has prioritized drug development and operations within the federal, FDA-regulated model, many jurisdictions already permit businesses to offer psychedelic experiences. In this session, we will hear stories from Oregon and international locations where psychedelic centers are already operating.

Kim Roddy, MBA

Co-Founder and Chief Operating Officer, Sunstone Therapies

Gregory Scott Kearns

Founder & Principal Consultant, Forth Road Health

Chair, Alchemy Community Therapy Center Board of Directors

Concluding remarks

Adjourn

Doors open

Opening remarks

Julie Holland, MD

Psychiatrist and Author, Good Chemistry

Opening address

Opening keynote: Studying MDMA-assisted therapy for PTSD within veteran populations

Jason Pyle, MD, PhD

Executive Director, Healing Breakthrough

Paula Schnurr, PhD

Executive Director, National Center for PTSD

Latest developments in clinical studies

Depression continues as a major unmet medical need in the US and globally. However, the majority of these patients do not receive adequate improvement from currently available medications – with only a third of patients with major depression receiving a full response to a first antidepressant and a third who fail to adequately respond to multiple medications given either concurrently or sequentially. Those who do respond to medication often lose the effect over time or develop side effects that impair quality of life, and when patients discontinue these medications, they are at very high risk of having the symptoms of depression return. In addition to these disappointing outcomes, mental health-related costs have a substantial impact on our economic system and society.

Psychedelic therapies have the potential to change our current approach to mental health care. Current research suggests that new treatments, such as psilocybin, could have a significant and positive impact on major depressive disorder. And follow-up studies after therapy have also shown lasting benefits.

In this session, we will draw on the latest developments in clinical research to prompt the audience to consider key questions, challenges, and opportunities as we move into a new era of mental health treatment with psychedelic therapies in treatment of depression.

Tura Patterson, MA

Senior Director of Strategic Partnerships, Usona Institute

Charles L. Raison, MD

Professor, psychiatrist, Director of Clinical and Translational Research, Usona Institute

A Historical Lens & Clinical Trial Findings: Ibogaine's Role in Methadone Treatment

Methadone is an opioid with an exceptionally long half-life, commonly used in the treatment of opioid dependence, such as heroin or fentanyl. Europe experienced a pervasive heroin epidemic from the 1970s through the 2000s. A substantial number of individuals with heroin use disorder entered Methadone Maintenance Programs (MMPs) as a means to taper off the drug. Remarkably, a significant proportion of individuals who previously had heroin use disorder remained enrolled in MMPs for years. In some cases, they were on methadone for decades and inadvertently developed iatrogenic dependence.

The reasons that prevented further research on ibogaine were, in the beginning of the 20th century, probably related to the stigma that hallucinations were carrying, as well as the racism that likely hindered the expansion of use of an African drug. These societal biases stifled the serious scientific investigation of ibogaine's potential to address substance use disorders.

In the recent decades, it is also true that after the serendipitous re-discovery of the anti-addictive effects of ibogaine, a patent fight was started between different actors. This legal battle created significant roadblocks and limited further and expanded research into ibogaine's potential as a treatment for methadone dependence. Such conflicts divert resources and create legal barriers, hindering progress in the field.

ICEERS has recognized these historical and contemporary obstacles and is committed to addressing them. We have developed an ibogaine-based treatment protocol tailored to individuals who wish to discontinue methadone. My talk will present historical anecdotes regarding the obscure early clinical utilization of ibogaine, shedding light on how societal biases have influenced research priorities. Subsequently, I will evaluate the evidence supporting ibogaine's efficacy in treating methadone dependence, despite the challenges it has faced. I will then provide an overview of our protocol and preliminary findings from our Phase II clinical trial, demonstrating our dedication to advancing research in this area. I will conclude by highlighting results from other research that explores the subjective effects of ibogaine in greater depth, emphasizing the importance of a holistic approach to substance use disorder treatment in the face of historical and contemporary challenges.

José Carlos Bouso, PhD

Scientific Director, ICEERS

Mid-morning break

Designing a state-funded, open-label psilocybin trial for diverse populations in the United States

In this brief presentation, Dr. Terence Ching will unveil the rationale and development process for a state-funded, open-label psilocybin trial for diverse populations in the United States. Specifically, he will cover key eligibility criteria and culturally attuned study design motivations for this first-of-its-kind trial that the Emerging and Novel Applications for Consciousness-Altering Therapeutics (ENACT) Lab and the Yale Program for Psychedelic Science, as co-directed by Dr. Jamila Hokanson, Dr. Ben Kelmendi and Dr. Chirstopher Pittenger, will spearhead in Connecticut. 

Terence Ching, MD

Associate Research Scientist, Yale School of Medicine

Perspective on psychedelic-assisted therapy in adolescent populations

In this brief presentation, Dr. Jamila Hokanson, will provide a perspective on Adolescent mental health from both a psychiatric and public health lens and discuss the potential risk and benefits of using psychedelic-assisted therapies in minors. She will also review a potential research design to determine the safety and feasibility of psychedelic-assisted therapy in an Adolescent population.

Jamila Hokanson, MD, MBA, MHA

Co-Director, Yale Center for Psychedelic Research

Emerging indications for psychedelic therapies

In the last fifteen years, psychedelics have been primarily investigated for treatment of depression, anxiety, and PTSD. More recently, research programs are exploring psychedelic therapies for other psychological and neurological disorders and illnesses, including obsessive compulsive disorder, Alzheimer’s disease, Lyme disease, adjustment disorder, and eating disorders. Join us to learn more about the new frontiers of clinical applications for psychedelics.

Lunch

The varieties of psychedelic neuroscience

As the profile of psychedelics continues to grow in both clinical discourse and popular culture, the quest for the underlying mechanisms of their effects has arrived as a matter of public interest.

Over the last decade, a series of findings from neuroimaging studies has yielded a variety of interpretations of the source of their therapeutic potential. These theories have often been breathlessly reported by the press and industry in service of advancing the plausibility of psychedelic medicine.

However, no consensus exists among the neuroscience community as to the origins of psychedelics effects and benefits, and neuroimaging is only one tool among many for investigating further.

In this session, we will hear from a panel of neuroscientists working towards a better understanding of underlying mechanisms about how to better consider and interpret the state of psychedelic neuroscience.

Daniela Schiller, PhD

Professor, Icahn School of Medicine at Mount Sinai

Gaurav Patel, MD, PhD

Director, DSC Lab

The enigma of psychedelic trial design

Psychedelics are a sui generis class of drugs whose effects and best practices were not anticipated by typical regulatory assumptions and trial designs. What lessons have scientists learned from decades of research and data, and how will the next generation of trials and studies offer more robust findings and valuable data? Join us to consider how researchers are innovating and moving the field forward.

Natalie Gukasyan, MD

Assistant Professor of Psychiatry, Columbia University

Boris D. Heifets, MD, PhD

Assistant Professor, Stanford University

Harriet de Wit, PhD

Professor, Department of Psychiatry and Behavioral Neuroscience, University of Chicago

Mid-afternoon break

Therapy, therapeutics, and psychedelics

After nearly two decades of renewed study of psychedelics based on methodologies whose roots stretch back to mid-century psychologists, new dialogues are emerging about how to best unlock and understand the therapeutic potential of psychedelics.

Alongside a renewed focus on investigating mechanisms of action, the development of psychedelic-inspired non-visionary drugs, and the challenges of pursuing a novel drug+therapy combination treatment, new questions are now being raised as to the centrality of psychotherapy in the healing process. Join us as we hear from therapists and scientists who are seeking to decipher the essential elements of psychedelic therapy.

Rachel Yehuda, PhD

Professor of Psychiatry and Neuroscience; Director, Center for Psychedelic Psychotherapy and Trauma Research

Grand panel

Closing remarks

Adjourn

Doors open

Opening remarks

Juliana Mercer

Director, Veteran Advocacy & Public Policy, Healing Breakthrough

BOD, Heroic Hearts Project

Opening address

What will people think? Revealing public knowledge, belief, and perceptions of psychedelics

As the psychedelic field experiences exponential growth, many of its goals will be directly affected in significant ways by what the general public knows and believes about psychedelic substances. But aside from narrowly focused opinion research tied to specific political efforts, the field has not had an evidence-based understanding of those public perceptions and knowledge. Until now. In this session, Berkeley Center for the Science of Psychedelics executive director Imran Khan will present the findings of the inaugural Psychedelic Insight Poll, a national baseline survey that serves as the cornerstone of a multi-year opinion research program launched by BCSP in 2023 to provide the entire psychedelic community with data-driven insights into the general public's beliefs, hopes, fears, and questions about psychedelics and psychedelic therapies. The Psychedelic Insight Poll will be conducted annually to more fully understand public perceptions, track how those perceptions shift over time, and examine how current events, research discoveries, media and communications efforts, business strategies, and other activity in the field are influencing those shifts.

Imran Khan

Executive Director, UC Berkeley Center for the Science of Psychedelics

Bringing psychedelics to Congress

More than fifty years after the passage of the Controlled Substances Act, a bipartisan team of legislators is asking their colleagues in US Congress to reevaluate the scheduling of certain psychedelics based on their potential for therapeutic applications.

Will the 119th Congress yield better alignment with the last two decades of scientific research, and the FDA's Breakthrough Designation for studies of MDMA and psilocybin in 2017 and 2018? Join us as we consider the Breakthrough Therapies Act.

Possibilities and policies in federal engagement with psychedelics

For decades, the federal government has declined to adopt any policies specific to psychedelics.

By default, prohibition and abstinence have been the official positions across every administration, but more than that-- psychedelics have simply garnered very little interest from government executives in recent decades.

Now, with the swell of research centers, clinical trials, veteran advocacy, statewide and local regulatory initiatives, NIH grants, congressional action, and increasing patterns of usage among the public, the federal government may need to engage with questions unique to psychedelics in America.

Join us to learn what it might look like for the many arms and agencies of the US government to address psychedelics at a time when their therapeutic potential is increasingly recognized, and the preeminence of prohibition is no longer presumed.

Mid-morning break

State initiatives to support psychedelic research and access

A dramatic expansion of psychedelic policy activism is underway at the state level.

Over a dozen states have recently considered legislation addressing psychedelics, including bills proposing research funding, decriminalization, regulated adult use, and more. Join us to learn about the variety of initiatives underway, and how legislators and activists consider and design strategies unique to their state.

Christine Diindiisi McCleave, MA

Doctoral Student and Consultant, University of Alaska Fairbanks

W. Bryan Hubbard, JD

Chairman and Executive Director, Kentucky Opioid Abatement Advisory Commission

Natasia Poinsatte

Colorado State Director, Healing Advocacy Fund

Tamar Todd

Legal Counsel, New Approach

Oregon Updates from the First Year of Regulated Access to Psilocybin Services

In November 2020, Oregon made history when its voters passed Ballot Measure 109, now known as the Oregon Psilocybin Services Act. This created a statewide regulatory system to support a market for supervised psilocybin experiences.

This year, after two years of rulemaking and planning, the Oregon Health Authority (OHA) has now licensed manufacturers, analysis laboratories, training programs, facilitators, and service centers, fulfilling the vision established in Measure 109. Join us to hear an update from the first year of operations from Angela Allbee, Oregon Psilocybin Services Section Manager at the Oregon Health Authority.

Angela Allbee, MPA
Manager, Oregon Psilocybin Services

Lunch

Educating the next generation of psychedelic therapists

The presence of a skilled psychedelic facilitator and the establishment of rapport are key elements in the positive therapeutic outcomes. Ensuring high-quality industry-wide standards of training will be a priority for the success of this treatment modality. Join us to consider the strategies of preparing the next generation of psychedelic facilitators.

NiCole T. Buchanan, PhD
CEO and Interim Board Chair, Board of Psychedelic Medicine and Therapies (BPMT)

Kelley O'Donnell, PhD
Assistant Professor of Psychiatry, Director of Clinical Training, NYU Langone Center for Psychedelic Medicine

The legalities of religious use of psychedelics in America

In recent years, the medical model has reigned supreme over dialogue, legislation, and funding of psychedelics in America. And yet, there exists another uniquely American route to the legal use of psychedelics: religious practice, protected by the First Amendment.

A patchwork of federal legislation and judicial precedents, including the unanimous UDV vs. USA Supreme Court ruling in 2006, uphold the ability to use psychedelics within sincere religious contexts. However, the existing legal affirmations were very hard-won for their petitioners, and there exists much gray area in determining to whom and how they apply, and much risk for groups seeking clarity. In this session, we will consider the legal relationship between religious freedom and spiritual practices that use psychedelics.

Allison Hoots

Attorney, Hoots Law Practice PLLC; President, Sacred Plant Alliance

Forrest Tadooahnippah

Professor, Mitchell Hamline School of Law

Mid-afternoon break

Class, classism, and psychedelics in America

The much-touted "psychedelic renaissance" of the last two decades has primarily been an upper middle class phenomenon.

Throughout the non-Indigenous psychedelic landscape, organizational leaders and executives, scientific investigators and study participants, media figures and spokespersons, gatekeepers and funders, and visitors to underground and offshore retreat centers typically come from similar affluent, educated, insular cultures.

While there has been much discussion in recent years of social justice, equity, and access, these initiatives are rarely designed by the communities they seek to aid, and hard discussions about class and privilege are often swept under the rug of technocratic systems and metrics. Join us as we listen to leaders who seek to bring psychedelics into their communities on their own terms.

Session TBA

Closing remarks

Adjourn

Doors open

Opening remarks

Bia Labate, PhD

Anthropologist, Co-Founder and Executive Director, Chacruna Institute

Opening address

International psychedelic policy updates

Throughout the world, public policy towards psychedelics is shifting in response to the growing scientific evidence, changing public perceptions, and the emergence of post-prohibitionist attitudes. In this session, we will hear updates from new initiatives across the globe to support research, access, public education, and decriminalization of psychedelics.

Psychedelic Parenthood: Why are we leaving children and adolescents out of the psychedelic renaissance?

The field of psychedelics is growing fast and widely, and thousands of the individuals forming part of this movement happen to be mothers, fathers and caregivers to children . Ethnographic reports indicate that the psychedelic experience can help these people deal with challenging realities such as imposter syndrome and maternal guilt and positively re-signify the experience of parenting. We also know that there are several traditional cultures where psychedelics are an integral part of community life, and may also be used during pregnancy and childbirth, as is the case of the Santo Daime tradition of midwifery, and in breastfeeding, as practiced by Wixárika mothers.Despite this, the Western psychedelic mainstream still has difficulties in including children, adolescents, and psychedelic families in its spaces, discussions, and scientific research. Based on the direct empirical experience of the author, who is the father of three children born and raised in a psychedelic context and culture in Brazil, this presentation offers 10 points of reflection which demonstrate the need for us to start talking more about psychedelic parenthood in the Psychedelic Renaissance. They address both the potential and risks of scientific research and therapy with psychedelics for children and adolescents, and social, economic, and decolonial aspects related to the inclusion of psychedelic families, especially children and mothers, in the psychedelic field.

Glauber Loures de Assis, PhD

Associate Director, Chacruna Institute Latinoamérica

Mid-morning break

Reflections on 35 years of psychedelic activism

Since the mid-nineties, Robert Jesse has been an instrumental figure in advocacy, activism, and scientific research related to psychedelics, including the importance of recognizing their value outside the context of medicine.

In 1995, he led the development of a Code of Ethics for Spiritual Guides. Later, Jesse was instrumental in forming the psilocybin research team at Johns Hopkins and has co-authored several of its papers, including “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance” (2006). In 2005, he led the writing of an amicus brief for the U.S. Supreme Court in the União do Vegetal religious liberty case, decided 8-0 favoring the church. In 2017, Bob led the drafting of a public statement, now signed by numerous leaders in the field, raising Open Science as a psychedelic ideal.

Earlier in life, Bob trained at Hopkins in electrical engineering and computer science, consulted for AT&T Bell Labs, and worked at Oracle, lastly as a VP of business development.

Robert Jesse

Advisor, CSP, Johns Hopkins, UC Berkeley

From personal to collective: ayahuasca as a peace-making tool among Palestinians and Israelis

In the spring of 2022, three groups of Palestinians and Israelis were invited to participate in an ayahuasca peacebuilding program. The invitation was to explore the ceremonial and healing space of ayahuasca through a collective intention: to ground the transformative spiritual practice in the political reality of conflict and oppression; to heal collective trauma and liberate from rigid narratives and ethos; to invite revelations and transform them into actions of co-resistance; to create a community of solidarity and care; and to celebrate life and good music together.

In this joint presentation, Sami Awad, a Palestinian peace activist and one of the leading facilitators, will present the program – tailored for this intention - and discuss the processes the groups went through. Leor Roseman, an Israeli psychedelic researcher from Imperial College London, will present quantitative, qualitative, and phenomenological research findings from the program.

The presentation will reveal how psychedelics can be used intentionally for socio-political endeavors beyond personal healing.

Sami Awad

Peace Activist, Holy Land Trust

Leor Roseman
Psychedelic Researcher, Centre for Psychedelic Research, Imperial College London

Lunch

Indigeneity, shamanism, and the enigma of authenticity

Standing at the nexus of a social justice movement demanding increased recognition for indigenous people and a vogue for all things natural, ancient, and ecologically-attuned, increasing numbers of people are seeking psychedelic experiences under the care of lineage-holding shamans, or ceremonies influenced by indigenous traditions.

However, the history and present of these traditions and practitioners are often more complex and dynamic than portrayed. The politics of indigenous communities, and even the concept of indigeneity itself, can also present unexpected puzzles.

In this session, we will explore the hard questions raised by interactions between indigenous communities with shamanic traditions, and the seekers of authenticity arriving on their doorstep.

Manvir Singh, PhD

Assistant Professor of Anthropology, UC Davis

Conspirituality: On the paranoid style in psychedelic politics

Despite much cleansing of the public perception of psychedelics (and their users) has occurred in recent decades, a varied and rich psychedelic subculture is also very much alive and well. While most facets of this world are healthy and creative communities who bond over shared values, traditions, and tastes, there also exist darker corners. The unique brew of a cultural legacy of anti-government sentiment, hardened by decades of unfair prohibitionist policy, denial of scientific fact about psychedelics, and unethical government-sponsored mid-century experiments, combined with intensity of the psychedelic experience, had led many down the path less traveled towards unhinged conspiracy theory. Join this session to shine light on the shadows cast by psychedelic illumination.

Mid-afternoon break

Cultural perspectives on psychedelics

Outside of both clinical contexts and indigenous traditions, psychedelics have a rich history of use in North America. The cultures and practices that have developed around these substances, so often marginalized, are now finding new popularity. What makes these milieus unique, and how do they continue to evolve? Join us to hear artists, journalists, and community leaders share insights about the people and practices that make up these diverse psychedelic cultures.

Cultural perspectives on psychedelics

Outside of both clinical contexts and indigenous traditions, psychedelics have a rich history of use in North America. The cultures and practices that have developed around these substances, so often marginalized, are now finding new popularity. What makes these milieus unique, and how do they continue to evolve? Join us to hear artists, journalists, and community leaders share insights about the people and practices that make up these diverse psychedelic cultures.

Concluding remarks

Adjourn

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

presented by horizons pbc, a public benefit corporation

presented by horizons pbc, a public benefit corporation

presented by horizons pbc, a public benefit corporation

presented by horizons pbc, a public benefit corporation

presented by horizons pbc, a public benefit corporation

presented by horizons pbc, a public benefit corporation

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

part of the fifteenth annual horizons conference

presented by horizons pbc, a public benefit corporation

horizons

the psychedelics business forum

wednesday, october 12, 2022
thursday, october 13, 2022

the new york academy of medicine
new york city

horizons

psychedelics in research

friday, october 14, 2022

the great hall at the cooper union
new york city

horizons

classes and workshops

wednesday, October 12, 2022
thursday, October 13, 2022

the new york academy of medicine
new york city

horizons

psychedelics in medicine

saturday, october 15, 2022

the great hall at the cooper union
new york city

horizons

psychedelics in the world

sunday, october 16, 2022

the great hall at the cooper union
new york city